New drug combo aims to shrink stomach tumors before surgery
NCT ID NCT07569068
First seen May 12, 2026 · Last updated May 17, 2026 · Updated 1 time
Summary
This study tests two drug combinations given before surgery for people with a specific type of advanced stomach or gastroesophageal junction cancer that has a protein called claudin 18.2. About 88 participants will receive either tislelizumab plus LM-302 and S-1, or tislelizumab plus SOX. The goal is to see which combination better eliminates cancer cells in the removed tumor and lymph nodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Huangpu District, 200025, China
Conditions
Explore the condition pages connected to this study.